- Home
- APLT
as 10-08-2025 9:37am EST
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 178.6M | IPO Year: | 2019 |
| Target Price: | $4.13 | AVG Volume (30 days): | 11.7M |
| Analyst Decision: | Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.48 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.29 - $10.62 | Next Earning Date: | 11-06-2025 |
| Revenue: | $121,000 | Revenue Growth: | -95.45% |
| Revenue Growth (this year): | -25.28% | Revenue Growth (next year): | 5931.24% |
Latest Applied Therapeutics Inc. News
APLT Breaking Stock News: Dive into APLT Ticker-Specific Updates for Smart Investing
Simply Wall St.
4 days ago
Institutional investors may adopt severe steps after Applied Therapeutics, Inc.'s (NASDAQ:APLT) latest 19% drop adds to a year losses
MT Newswires
4 months ago
Applied Therapeutics Promotes Evan Bailey to Chief Medical Officer
GlobeNewswire
4 months ago
Applied Therapeutics Announces Key Leadership Appointments
GlobeNewswire
5 months ago
Applied Therapeutics Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late-Breaking Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting
GlobeNewswire
5 months ago
Applied Therapeutics Reports First Quarter 2025 Financial Results
GlobeNewswire
5 months ago
Applied Therapeutics Announces Acceptance of Late-Breaking Abstract for Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting
GlobeNewswire
6 months ago
Applied Therapeutics Reports Fourth Quarter and Year-end 2024 Financial Results
Bloomberg
6 months ago
Russell 2000 Enters Bear Market With Small Caps Stung by Tariffs
Compare APLT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "APLT Applied Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.